Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, phase I clinical trial.

https://pubmed.ncbi.nlm.nih.gov/33098996/

Authors: Hiltbrunner S, Bristchgi C, Schuberth P, Bankel L, Nguyen-Kim TDL, Gulati P et al.

Ann Oncol 2021;32(1):120-121